Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Androxal in Men with Secondary Hypogonadism
NCT01534208Phase 3Completed
- Sponsor
- Repros Therapeutics Inc.
- Start
- May 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enclomiphene in secondary hypogonadism (HH), sponsored by Repros Therapeutics Inc.. Started May 2012; status: completed.
02
Drugs
enclomiphene
03
Conditions
secondary hypogonadism (HH)
Beyond the preview
Go deeper on NCT01534208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534208.